Name: HOXB7 8-25
Price: 298.00 USD

- Overview
  - Targets HOXB7 expressing tumours.
    HOXB7 8 25 is a novel Homeobox B7 (HOXB7) derived peptide epitope, identified as having the potential to bind to multiple HLA-DRs (DR1, 4, 7, 11, and 15) and target HOXB7 expressing tumours through immune cells. HOXB7 is a master regulatory gene that regulates cell proliferation and activates oncogenic pathways, and overexpression of HOXB7 correlates with poor prognosis in cancer. In human head and neck squamous cell carcinoma (HNSCC) tissue HOXB7 8-25 shows direct cytotoxicity and antigen specific and tumour reactive promiscuous CD4+ T cell responses, producing -interferon and directly killing tumours through granzyme B. HOXB7 is thus demonstrated to be a potential target for cancer immunotherapy.
    
    Please contact us for availability.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Nuclear Receptor Modulators
    
    Alternative Name
    
    HOXB7(8-25), HOXB7 peptide
    
    Molecular Formula
    
    C75H135N19O20
    
    Molecular Weight
    
    1622.01
    
    Appearance
    
    Freeze dried solid
    
    Purity
    
    >95% by HPLC
    
    Solubility
    
    Soluble in DMSO
    
    Other Properties
    
    Sequence: H-Pro-Leu-Leu-Leu-Lys-Leu-Leu-Lys-Ser-Val-Gly-Ala-Gln-Lys-Asp-OH,PLLLKLLKSVGAQKD
    
    Storage
    
    Store dry, frozen and in the dark
    
    * Please note: this product can only be supplied to registered research and development facilities, and may be used for in vitro research use only, not for administration to humans or animals.

HOXB7 8-25

HOXB7 8-25

We Also Recommend

EPI-X4

S9pep

VGN50